Not sure we could raise enough funds from selling snags. I think...

Not sure we could raise enough funds from selling snags. I think below would work hahahahhaha

GoFundMe Campaign: Save IMU – One Shareholder at a Time

Goal: $100,000,000
Raised so far: $0.022 and 7.44 billion IOUs

Created by: Long-Suffering Retail Holders Anonymous

About the Campaign

Welcome to the official GoFundMe for Imugene Limited (IMU) — your favourite ASX-listed biotech promising to revolutionise cancer treatment, just as soon as it can afford to keep the lights on.

We are not here to cure cancer (yet). We are just here to fund the data needed to raise the money to maybe fund the data again. You know the drill.

Where Will Your Money Go?

Your generous donation will be used to support:

• Three concurrent clinical trials — because choosing one is for quitters

• Milestone payments to Precision for things we hope to achieve someday

• Susquehanna’s early retirement fund

• Executive salaries, which are unaffected by market cap, performance, or gravity

• A new PowerPoint template for our next “transformational” investor presentation

• Cutting-edge science... if there’s enough left over

Perks for Donors

$10: We will send you a PDF of our next ASX announcement. It’s mostly buzzwords, but it’s shiny.

$100: Your name etched into the back of a lab notebook, next to the word "optional."

$1,000: A one-on-one session with the CFO to explain how dilution is actually good for you.

$5,000: Free retail access to the next raise. Just kidding. Institutions only.

$10,000 – The Lesley Loyalty Pack: You all receive a limited-edition “Trust the Science” hoodie, a scented candle that smells like “mild recovery,” and a pre-recorded ASX announcement narrated by your favourite biotech executive. Comes with early access to the next glass-half-full interpretation of trial results.

$25,000 – The PH Legacy Tier: Join the elite “Cap Raisers Club,” complete with a playbook titled "How to Guide Biotech from Hope to Halt." Includes a gold-plated calculator to track shareholder value erosion and a seat at the virtual table for designing your next biotech detour. Also comes with a framed chart from one of your previous companies. Spoiler: it's red.

Stretch Goals

• $200M: Dual-listing on NASDAQ so we can underwhelm on two continents

• $300M: A Phase 2 trial before the patents expire

• $500M: The CFO gets a new calculator that rounds up

Why Contribute?

Because you are still here.
Because you have said, “one more announcement” 37 times.
Because hope isn’t a strategy, but it’s all we have got left.
Because you’re not ready to tell your partner you backed a company with 7.4 billion shares on issue.
Because deep down, you still believe in the science… kind of.

Donate now. Help us get from dilution to... slightly less dilution.